Chronic Interstitial Cystitis
Conditions
Brief summary
To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).
Detailed description
Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.
Interventions
OTHERPentosan Polysulphate
300mg 3 times a day
Sponsors
Hisar Intercontinental Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
two models: with and without Hunner's ulcer
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Chronic interstitial cystitis * Bladder Pain Syndrome
Exclusion criteria
* Acute cystitis * Bladder cancer * Chronic prostatitis * Bladder stone * Stress incontinence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| bladder wall thickness | Three months | 0.3 over 3 mm 1 under 3 mm, |
| improvement of lower urinary tract symptoms | Three months | 1 if symptoms improved, 0 if not |
Countries
Turkey (Türkiye)
Outcome results
None listed